CP
NEO icon

Castleview Partners’s NeoGenomics NEO Stock Holding History

Castleview Partners’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$82K Buy
+1,820
New +$80.6K 0.04% 325

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Castleview Partners's NEO Position: Q2 2021 in Review

Castleview Partners opened a new position in NeoGenomics (NEO) in Q2 2021: 1,820 shares worth $82K. The stake represents 0.04% of the portfolio and ranks #325 among its holdings.

311 funds tracked by Wall St. Rank hold NEO as of Q2 2021.

  • Castleview Partners held 1,820 shares of NeoGenomics worth $82K as of Q2 2021.
  • NeoGenomics was a new Castleview Partners position in Q2 2021.
  • NeoGenomics made up 0.04% of Castleview Partners's portfolio in Q2 2021, its #325 holding.
  • 311 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.